Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

NCT02959476 is registered in ClinicalTrials.gov with BioQ Pharma, Inc. as lead sponsor.

NCT NCT02959476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery
Lead sponsor
BioQ Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 13, 2017
Completion date
August 10, 2018
Enrollment
132 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

pain, postoperative